Testing RAP-219 for Focal Seizure Control in Adults
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and have a healthy weight range (BMI 18–45)
- You have been diagnosed with focal epilepsy for at least 2 years
- You have had a brain scan (MRI or CT) and an EEG test within the past 10 years that confirm focal epilepsy
- You are currently taking 1–3 seizure medications as ongoing treatment (not just rescue medications)
- You can keep daily records of your seizures using a smartphone app or online diary
- You have not had epilepsy surgery in the past 12 months and don't plan to have surgery during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
This study looks at how epilepsy affects a brain chemical that helps control breathing and alertness. It uses a special scan to see this chemical, which may help find better treatments for seizures.
Hear when a new Focal Seizure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.